A detailed history of Quadrant Capital Group LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Quadrant Capital Group LLC holds 1,120 shares of SAGE stock, worth $6,137. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,120
Previous 336 233.33%
Holding current value
$6,137
Previous $3,000 166.67%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$7.02 - $13.08 $5,503 - $10,254
784 Added 233.33%
1,120 $8,000
Q2 2024

Aug 12, 2024

BUY
$10.58 - $17.9 $3,554 - $6,014
336 New
336 $3,000
Q3 2023

Nov 14, 2023

BUY
$16.75 - $48.98 $10,837 - $31,690
647 Added 1540.48%
689 $14,000
Q2 2023

Aug 09, 2023

SELL
$40.65 - $59.54 $813 - $1,190
-20 Reduced 32.26%
42 $1,000
Q1 2023

May 11, 2023

BUY
$37.27 - $46.57 $745 - $931
20 Added 47.62%
62 $2,000
Q4 2022

Feb 10, 2023

SELL
$32.2 - $43.61 $805 - $1,090
-25 Reduced 37.31%
42 $1,000
Q2 2022

Aug 09, 2022

BUY
$27.52 - $37.99 $1,155 - $1,595
42 Added 168.0%
67 $2,000
Q1 2022

May 06, 2022

SELL
$30.71 - $45.71 $1,044 - $1,554
-34 Reduced 57.63%
25 $1,000
Q4 2021

Feb 01, 2022

BUY
$37.06 - $47.11 $1,148 - $1,460
31 Added 110.71%
59 $3,000
Q3 2021

Nov 12, 2021

SELL
$40.26 - $57.37 $1,288 - $1,835
-32 Reduced 53.33%
28 $1,000
Q2 2021

Aug 09, 2021

SELL
$54.88 - $79.29 $493 - $713
-9 Reduced 13.04%
60 $3,000
Q1 2021

May 12, 2021

SELL
$70.65 - $96.76 $847 - $1,161
-12 Reduced 14.81%
69 $5,000
Q4 2020

Feb 16, 2021

BUY
$58.41 - $89.06 $876 - $1,335
15 Added 22.73%
81 $7,000
Q3 2020

Nov 13, 2020

BUY
$41.13 - $62.45 $1,686 - $2,560
41 Added 164.0%
66 $4,000
Q2 2020

Aug 13, 2020

SELL
$25.95 - $43.15 $2,205 - $3,667
-85 Reduced 77.27%
25 $1,000
Q1 2020

May 15, 2020

BUY
$26.15 - $77.24 $2,693 - $7,955
103 Added 1471.43%
110 $3,000
Q4 2019

Feb 03, 2020

SELL
$60.18 - $154.77 $10,170 - $26,156
-169 Reduced 96.02%
7 $0
Q3 2019

Oct 24, 2019

SELL
$140.29 - $189.96 $24,129 - $32,673
-172 Reduced 49.43%
176 $23,000
Q1 2019

Apr 29, 2019

BUY
$89.33 - $163.65 $30,461 - $55,804
341 Added 4871.43%
348 $53,000
Q4 2018

Jan 17, 2019

BUY
$81.94 - $139.71 $573 - $977
7 New
7 $0

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $326M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Quadrant Capital Group LLC Portfolio

Follow Quadrant Capital Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quadrant Capital Group LLC with notifications on news.